Primary Hyperparathyroidism malady

NIH Rare Diseases: Hyperparathyroidism is an endocrine disorder in which the parathyroid glands in the neck produce too much parathyroid hormone (PTH). Signs and symptoms are often mild and nonspecific, such as a feeling of weakness and fatigue, depression, or aches and pains. With more severe disease, a person may have a loss of appetite, nausea, vomiting, constipation, confusion or impaired thinking and memory, and increased thirst and urination. Patients may have thinning of the bones without symptoms, but with risk of fractures. There are two main types of hyperparathyroidism: primary hyperparathyroidism and secondary hyperparathyroidism. Surgery to remove the parathyroid gland(s) is the main treatment for the disorder. Some patients with mild disease do not require treatment.³⁰

MalaCards: Primary Hyperparathyroidism, also known as hyperparathyroidism, primary, is related to humoral hypercalcemia of malignancy and hyperparathyroidism-jaw tumor syndrome. An important gene associated with Primary Hyperparathyroidism is CASR (calcium-sensing receptor), and among its related pathways are Breast Cancer Regulation by Stathmin1 and Class B/2 (Secretin family receptors). The drugs prednisone pwdr [va product] and calcitriol and the compounds glucose and pamidronate have been mentioned in the context of this disorder. Affiliated tissues include bone marrow, whole blood and kidney, and related mouse phenotypes are respiratory system and endocrine/exocrine gland.

Wikipedia: Primary hyperparathyroidism causes hypercalcemia (elevated blood calcium levels) through the excessive...⁴⁴ more...

Aliases & Descriptions:

primary hyperparathyroidism 6 8 hyperparathyroidism, primary 30 17 43 familial benign hypercalcemia (disorder) 6 primary hyperparathyroidism (disorder) 6 familial primary hyperparathyroidism 6 familial benign hypercalcemia 43

familial hyperparathyroidism 43 hyperparathyroidism primary 32 primary hyperthyroidism 30 hyperparathyroidism 43 hypercalcemia 43

Diseases related to primary hyperparathyroidism by text searches and GeneDecks gene sharing:

(show top 50)    (show all 918)

id	Related Disease	Score	Top Affiliating Genes
1	humoral hypercalcemia of malignancy	33.7	BGLAP, FGF23, CASR, TNF, TNFSF11, PTH1R
2	hyperparathyroidism-jaw tumor syndrome	32.4	RET, CDC73, MEN1, CCND1, CASR
3	parathyroid carcinoma	32.0	CDC73, MEN1, CASR, PTH, CXADR
4	familial hypocalciuric hypercalcemia	32.0	CASR, NR1I3, CXADR
5	familial isolated hyperparathyroidism	31.9	RET, CDC73, MEN1, CASR, PTH, GAST
6	hypocalciuric hypercalcemia	31.8	CASR, CALCA, PTH, NR1I3, PRKAR1A, CXADR
7	hyperparathyroidism, neonatal severe primary	31.2	CASR, NR1I3, PRKAR1A, CXADR
8	squamous cell carcinoma	30.7	GC, CHGA, CDKN1B, IL6R, CCND1, IGFBP1
9	multiple myeloma	30.2	IL6, CCND1, TNFSF11, ABCB1
10	secondary hyperparathyroidism of renal origin	29.9	VDR, BGLAP, B2M, CD36, FGF23, MEN1
11	acute lymphoblastic leukemia	29.8	KITLG, PAX5, IL6R, IGFBP1, PTHLH, ABCB1
12	parathyroid adenoma	29.5	RET, GCM2, VDR, BGLAP, CHGA, CDC73
13	multiple endocrine neoplasia type 2a	29.3	RET, CALCA, NF1
14	follicular adenoma	29.2	RET, MEN1, IL6R, PTHLH, TG
15	mccune albright syndrome	29.2	GNAS, GH1, PRL
16	papillary thyroid carcinoma	28.9	RET, MEN1, CCND1, CALCA, TG, CXCL12
17	neurofibromatosis	28.8	RET, KITLG, BRCA2, MEN1, SST, NF1
18	pancreatic cancer	28.6	RET, BRCA2, CHGA, MEN1, CCND1, IAPP
19	osteomalacia	28.5	KL, GC, VDR, BGLAP, CD36, FGF23
20	papilloma	28.4	RET, BRCA2, CD36, CDKN1B, MEN1, CCND1
21	dysgerminoma	28.3	KITLG, BRCA2, ALPP, PTHLH, CYP27B1, PRL
22	multiple endocrine neoplasia	28.2	RET, BRCA2, CHGA, CDC73, CDKN1B, INS
23	liver cirrhosis	28.2	ALB, ALPP, F10, TNFRSF11B, SST, ADM
24	thymoma	28.1	CHGA, LBR, B2M, CALCA, PTHLH, SST
25	hypocalcemia	28.1	GCM2, VDR, BGLAP, CD36, FGF23, IAPP
26	hypoparathyroidism	27.8	RET, GCM2, VDR, BGLAP, INS, FGF23
27	hemangioma	27.8	RET, KITLG, VWF, SELE, CHGA, MEN1
28	ossifying fibroma	27.7	BGLAP, CDC73, GNAS
29	osteosclerosis	27.7	BGLAP, ALPP, TNFRSF11B, TNFSF11, PTH, PDLIM3
30	adult t-cell leukemia	27.6	SELE, B2M, CDKN1B, IL6, CCL27, CCND1
31	parathyroid disorders	27.6	RET, CDC73, MEN1, CASR, PTH, PTHLH
32	fibrous dysplasia	27.6	BGLAP, CD36, FGF23, IL6, ALPP, GNAS
33	hypophosphatasia	27.6	CCL27, ALPP, CALCA, SLPI
34	hypercalcemia	27.4	KL, GC, VDR, BGLAP, CHGA, B2M
35	osteitis fibrosa	27.4	BGLAP, B2M, ALPP, GNAS, CASR, CALCA
36	neuroendocrine tumor	27.2	RET, CHGA, MEN1, GNAS, CALCA, GH1
37	rhabdoid tumors	27.2	CHGA, CCND1, ALPP, CALCA, PTHLH
38	paraneoplastic syndromes	27.1	FGF23, IL6, ALB, CALCA, PTHLH, CSF3
39	pancreatic endocrine carcinoma	27.1	CALCA, PTHLH, SST
40	neuroendocrine carcinoma	27.1	PAX5, CHGA, MEN1, CALCA, SST, GAST
41	hypercalciuria	27.1	LRP2, KL, VDR, BGLAP, B2M, MIP
42	breast cancer	27.1	BRCA2, VDR, IL6, CCND1, TNF, NF1
43	t-cell leukemia	26.9	KITLG, SELE, PAX5, B2M, CDKN1B, IL6
44	bone cancer	26.9	VDR, CD36, ALPP, CALCA, TNFRSF11B, TNFSF11
45	mediastinitis	26.8	SELE, PAX5, IL6, ALPP, CALCA, PTH
46	cushing's syndrome	26.7	GH1, SST, POMC
47	medullary sponge kidney	26.7	RET, INS, PTHLH
48	non-hodgkin lymphoma	26.6	KITLG, VDR, PAX5, LBR, B2M, CDKN1B
49	nephrocalcinosis	26.6	LRP2, ALB, CASR, NR1I3
50	squamous cell carcinoma of the head and neck	26.5	SELE, CDKN1B, CCND1, PTHLH, NOS3, ABCB1

Approved drugs:

Drug clinical trials:

Inferred drug relations via UMLS/NDF-RT:

^43 28 calcitonin, calcitonin,salmon, calcitriol, cod liver oil [va product], dihydrotachysterol, doxercalciferol, edetate disodium, edta, edta tetrasodium, etidronate, etidronate disodium, gallium nitrate, pamidronate, pamidronate disodium, paricalcitol, plicamycin, prednisone, prednisone pwdr [va product], zoledronic, zoledronic acid

MalaCards organs/tissues related to primary hyperparathyroidism:

²²

MGI Mouse Phenotypes related to primary hyperparathyroidism:

²⁵ (show all 29)

id	Description	MGI Source Accession	Score	Top Affiliating Genes
1	respiratory system phenotype	MP:0005388	9.7	TH, PRKAR1A, NF1, PTH1R, CALCA, LRP2
2	endocrine/exocrine gland phenotype	MP:0005379	9.5	NF1, PRKAR1A, SLC26A6, PTH, GNAS, MEN1
3	pigmentation phenotype	MP:0001186	9.5	PRKAR1A, NF1, COL1A1, CASR, CDKN1B, KITLG
4	craniofacial phenotype	MP:0005382	9.5	PRKAR1A, NF1, PTH1R, PTH, GNAS, MEN1
5	embryogenesis phenotype	MP:0005380	9.3	PTH1R, COL1A1, NF1, PRKAR1A, PRL, CXADR
6	other phenotype	MP:0005395	9.1	ADM, ABCB1, NF1, NOS3, CAPN2, CASR
7	hematopoietic system phenotype	MP:0005397	8.8	COL1A1, NF1, TG, PRKAR1A, CXADR, CSF3
8	renal/urinary system phenotype	MP:0005367	8.8	LRP2, KL, RET, GCM2, CHGA, CDC73
9	no phenotypic analysis	MP:0003012	8.5	POMC, COL1A1, SST, PTH2R, GHRL, GNAS
10	limbs/digits/tail phenotype	MP:0005371	8.4	TNFRSF11B, TNFSF11, PTH, PTHLH, COL1A1, NF1
11	hearing/vestibular/ear phenotype	MP:0005377	8.2	CALCA, TNFRSF11B, COL1A1, NF1, ABCB1, GNAS
12	integument phenotype	MP:0010771	8.1	COL1A1, NF1, TH, PRL, CSF3, POMC
13	liver/biliary system phenotype	MP:0005370	7.3	CFTR, CD36, CDC73, INS, MEN1, IL6
14	nervous system phenotype	MP:0003631	7.3	CCND1, PTHLH, CRTAC1, COL1A1, NF1, TH
15	reproductive system phenotype	MP:0005389	7.1	CDKN1B, FGF23, MEN1, IL6, CCND1, ALPP
16	skeleton phenotype	MP:0005390	7.0	PTH, PTH1R, PTHLH, CYP27B1, PRKAR1A, SOST
17	muscle phenotype	MP:0005369	6.7	TNF, NOS3, COL1A1, NF1, PDLIM3, PRKAR1A
18	digestive/alimentary phenotype	MP:0005381	6.7	KCNQ1, LEP, LBR, B2M, CFTR, CD36
19	immune system phenotype	MP:0005387	6.6	CXADR, POMC, ADM, ADIPOQ, GAST, PRL
20	normal phenotype	MP:0002873	6.3	GNAS, CAPN2, GHRL, SST, COL1A1, NF1
21	tumorigenesis	MP:0002006	6.1	AIP, TNF, COL1A1, NF1, PRKAR1A, PRL
22	vision/eye phenotype	MP:0005391	6.1	CCND1, CASR, TNF, PTHLH, NOS3, COL1A1
23	adipose tissue phenotype	MP:0005375	6.0	IL6R, IGF1, GNAS, GH1, GHRL, TNF
24	mortality/aging	MP:0010768	5.4	LEP, LBR, CFTR, CD36, CDC73, CDKN1B
25	behavior/neurological phenotype	MP:0005386	4.9	COL1A1, NOS3, SST, PTHLH, GHRL, CALCA
26	growth/size phenotype	MP:0005378	4.4	LRP2, KL, RET, KITLG, SELE, SERPINE1
27	cardiovascular system phenotype	MP:0005385	3.5	TH, PRKAR1A, CXADR, CXCL12, POMC, ADM
28	cellular phenotype	MP:0005384	3.0	CXCL12, POMC, SLPI, ADM, ADIPOQ, EPO
29	homeostasis/metabolism phenotype	MP:0005376	0.7	SLPI, SLC26A6, ADM, ADIPOQ, EPO, GAST

Articles related to primary hyperparathyroidism:

(show top 50)    (show all 189)

id	Title	Authors	Year	Affiliating Genes
1	Comparisons of serum sclerostin levels among patients with postmenopausal osteoporosis, primary hyperparathyroidism and osteomalacia . (21667439)	Kaji H.... Seino S.	2011	SOST
2	Genes up- or down-regulated by high calcium medium in parathyroid tissue explants from patients with primary hyperparathyroidism. (19952464)	Nakajima K.... Sato K.	2010	PTH, CHGA, SPSB1
3	Could primary hyperparathyroidism-related hypercalcem ia induce hypercalcitoninemia? (20389108)	Conte-Devolx B.... Niccoli P.	2010	CALCA
4	High third generation/second generation PTH ratio in a patient with parathyroid carcinoma: clinical utility of third generation/seco nd generation PTH ratio in patients with primary hyperparathyroidism. (18782355)	Caron P.... Souberbielle J.C.	2009	PTH
5	Hypercalcemia of primary hyperparathyroidism was treated by cinacalcet in a patient with liver cirrhosis. (18561096)	Akinci B.... Tankurt E.	2009	CASR, CXADR
6	Endothelial function and endothelial nitric oxide syn thase intron 4a/b polymorphism in primary hyperparathyroidism. (19574729)	Ekmekci A.... Erbil Y.	2009	NOS3
7	Plasma 25-hydroxyvitamin D, 1,25-dihydroxyvitamin D, and parathyroid hormone in familial hypocalciuric hypercalcemia and primary hyperparathyroidism. (18787045)	Christensen S.E.... Mosekilde L.	2008	CASR
8	The role of the receptor activator of nuclear factor-kappaB ligand/osteoprotegerin cytokine system in primary hyperparathyroidism. (18073309)	Nakchbandi I.A.... Insogna K.L.	2008	IL6, TNFSF11, TNFRSF11B
9	Serum 1-84 and 7-84 parathyroid hormone concentration s and bone in patients with primary hyperparathyroidism. (18618138)	Blachowicz A.... Franek E.	2008	PTH
10	Normocalcemic, subclinical, asymptomatic primary hyperparathyroidism in patients with goiter or papillary thyroid cancer--preliminary report. Normocalcemic primary hyperparathyroidism and thyroid pathology. (17966885)	NiedA_wiecki S.... Pomorski L.	2007	SLPI
11	Pancreatitis in primary hyperparathyroidism-related hypercalcaemia is not associated with mutations in the CASR gene. (17853337)	Felderbauer P.... Schmidt W.E.	2007	CASR, NR1I3
12	P-glycoprotein expression is associated with sestamib i washout in primary hyperparathyroidism. (17929232)	Gupta Y.... Wishart G.C.	2007	ABCB1
13	Hypermethylation of adenosine triphosphate-binding cassette transporter genes in primary hyperparathyroidism and its effect on sestamibi imaging. (17299072)	Takeuchi H.... Singer F.R.	2007	ABCB1
14	Primary hyperparathyroidism--what the nephrologist should know--an update. (17138574)	Raue F.... Frank-Raue K.	2007	RET, MEN1, CDC73
15	Rapid mutation screening for HRPT2 and MEN1 mutations associated with familial and sporadic primary hyperparathyroidism. (17065424)	Howell V.M.... Marsh D.J.	2006	MEN1, CDC73
16	Primary hyperparathyroidism mimicking vaso-occlusive crises in sickle cell disease. (16882790)	Krishnamoorthy P.... Jabado N.	2006	CALCA
17	The gene expression and activity of calpains and the muscle wasting-associated ubiquitin ligases, atrogin-1 and MuRF1, are not altered in patients with primary hyperparathyroidism. (16865232)	Evenson A.... Hasselgren P.O.	2006	CAPN2, FBXO32
18	Regulation of plasma fibroblast growth factor 23 by calcium in primary hyperparathyroidism. (16381997)	Kobayashi K.... Nishizawa Y.	2006	FGF23
19	Primary hyperparathyroidism (16382970)	Carnevale V.... Mazzuoli G.	2005	CCND1
20	Primary hyperparathyroidism and neuropsychiatric alterations in a nonagenarian woman. (15847125)	Prete C.... Palummeri E.	2005	ALB
21	Adrenomedullin immunoreactivity tissue distribution in parathyroids of the patients with primary hyperparathyroidism. (15305232)	Letizia C.... Mazzuoli G.F.	2004	ADM
22	The effect of vitamin D status on the severity of bone disease and on the other features of primary hyperparathyroidism (pHPT) in a vitamin D deficient region. (15648543)	Raef H.... Chaudhry M.	2004	PTH
23	Genetic analyses of the HRPT2 gene in primary hyperparathyroidism: germline and somatic mutations in familial and sporadic parathyroid tumors. (15531515)	Cetani F.... Marcocci C.	2004	CDC73
24	A rare case of primary hyperparathyroidism with clear cell adenoma. (15118272)	Kanda K.... Tanaka Y.	2004	ALPP, PTH
25	Primary hyperparathyroidism. Update on pathophysiology, clinical presentation and surgical treatment. (15658669)	Farnebo L.O.	2004	CASR, NR1I3
26	Fibroblast growth factor 23, parathyroid hormone, and 1alpha,25-dihydroxyvitamin D in surgically treated primary hyperparathyroidism. (15595334)	Tebben P.J.... Kumar R.	2004	PAX5, FGF23
27	Raloxifene lowers serum calcium and markers of bone t urnover in postmenopausal women with primary hyperparathyroidism. (12629102)	Rubin M.R.... Silverberg S.J.	2003	BGLAP
28	The calcimimetic cinacalcet normalizes serum calcium in subjects with primary hyperparathyroidism. (14671147)	Shoback D.M.... Peacock M.	2003	NR1I3
29	Effects of nasal calcitonin on bone mineral density following parathyroidectomy in patients with primary hyperparathyroidism. (12784089)	Casez J.P.... Jaeger P.	2003	CALCA
30	Multiple endocrine neoplasia type 1 (MEN1) germline mutations in familial isolated primary hyperparathyroidism. (12699448)	Pannett A.A.J.... Thakker R.V.	2003	MEN1
31	A strategy for the management of elderly women with primary hyperparathyroidism: a comparison of etidronate therapy with parathyroidectomy. (11867933)	Horiuchi T.... Orimo H.	2002	BGLAP
32	Bisphosphonates and primary hyperparathyroidism. (12412793)	Rodan G.A.	2002	PTHLH
33	A novel six-nucleotide insertion in exon 4 of the MEN1 gene, 878insCTGCAG, in three patients with familial insulinoma and primary hyperparathyroidism. (12417605)	Okamoto H.... Kosugi S.	2002	MEN1
34	Calcium-sensing receptor gene polymorphisms in primary hyperparathyroidism. (12150336)	Cetani F.... Marcocci C.	2002	CASR, CXADR
35	The NeiI polymorphism in the cyclin D1 gene and sporadic primary hyperparathyroidism. (11902820)	Correa P.... Carling T.	2001	CCND1
36	Unique clinical characteristics of primary hyperparathyroidism in India. (11350446)	Mishra S.K.... Rastad J.	2001	PDLIM3
37	The distribution of two different vitamin D receptor polymorphisms (BsmI and start codon) in primary hyperparathyroidism. (10672140)	Sosa M.... Betancor P.	2000	VDR
38	Lack of relationship between BsmI vitamin D receptor polymorphism and primary hyperparathyroidism in a Spanish female population. (10441653)	MenA!rguez J.... Polo J.R.	1999	VDR, ALPP
39	Vitamin D receptor genotype is associated with cortical bone loss in Japanese patients with primary hyperparathyroidism. (9625456)	Kobayashi T.... Chihara K.	1998	VDR
40	A case of multiple endocrine neoplasia type I with primary hyperparathyroidism, prolactin secreting pituitary microadenoma and gastrin secreting duodenal carcinoid (9465604)	Tokumitsu M.... Yachiku S.	1997	PRL, GAST
41	Of bone and genes: vitamin D receptor polymorphism and primary hyperparathyroidism. (8766936)	Hofbauer L.C.... Heufelder A.E.	1996	VDR
42	Primary hyperparathyroidism. Concept, classification and symptomatology (7752472)	Fujita T.	1995	PTH
43	Changes in bone mass and metabolism after surgery for primary hyperparathyroidism. (7621568)	Garton M.... Reid D.	1995	PTH
44	Effects of infusion of parathyroid hormone and primary hyperparathyroidism on formation and breakdown of type I collagen. (7895178)	Brahm H.... Ljunghall S.	1994	CD36
45	Familial isolated primary hyperparathyroidism. (7955451)	Kassem M.... Kruse T.A.	1994	CALCA, PRL
46	The medical treatment of primary hyperparathyroidism (8488334)	Lo Cascio V.... Bertoldo F.	1993	CALCA
47	Combination therapy with pamidronate and calcitonin in hypercalcemic crisis caused by primary hyperparathyroidism (1462441)	Christensen J.H.... Kristiansen J.H.	1992	CALCA
48	Salmon calcitonin treatment by nasal spray in primary hyperparathyroidism. (1782100)	TA... SjAPberg H.E.	1991	CALCA
49	Serum osteocalcin levels in primary hyperparathyroidism. (1886398)	Pietschmann P.... Woloszczuk W.	1991	BGLAP
50	Falsely normal values of intact parathyrin in serum of patients with mild primary hyperparathyroidism? (2337997)	Minisola S.... Mazzuoli G.	1990	PTH

Genes related to primary hyperparathyroidism according to GeneCards:

(show top 50)    (show all 80)

id	Symbol	Description	Score	GeneCards Section Context
1	CASR	calcium-sensing receptor	11.1	Publications, Summaries
2	MEN1	multiple endocrine neoplasia I	11.0	Publications
3	PTH	parathyroid hormone	11.0	Publications
4	GCM2	glial cells missing homolog 2 (Drosophila)	11.0	Publications
5	CDC73	cell division cycle 73, Paf1/RNA polymerase II complex component, homolog (S. cerevisiae)	11.0	Publications
6	SOST	sclerostin	11.0	Publications
7	SLC26A6	solute carrier family 26, member 6	11.0	Publications
8	NR1I3	nuclear receptor subfamily 1, group I, member 3	11.0	Publications
9	CCL27	chemokine (C-C motif) ligand 27	11.0	Publications
10	AIP	aryl hydrocarbon receptor interacting protein	11.0	Publications
11	FGF23	fibroblast growth factor 23	11.0	Publications
12	BAAT	bile acid CoA: amino acid N-acyltransferase (glycine N-choloyltransferase)	11.0
13	PRSS1	protease, serine, 1 (trypsin 1)	11.0	Publications
14	PTH1R	parathyroid hormone 1 receptor	11.0	Publications
15	PRKAR1A	protein kinase, cAMP-dependent, regulatory, type I, alpha	11.0	Publications
16	FBXO32	F-box protein 32	11.0	Publications
17	MIP	major intrinsic protein of lens fiber	11.0	Publications
18	PDLIM3	PDZ and LIM domain 3	11.0	Publications
19	CYP27B1	cytochrome P450, family 27, subfamily B, polypeptide 1	11.0	Publications
20	CHGA	chromogranin A (parathyroid secretory protein 1)	11.0	Publications
21	CALCA	calcitonin-related polypeptide alpha	11.0	Publications
22	SPINK1	serine peptidase inhibitor, Kazal type 1	11.0	Publications
23	BGLAP	bone gamma-carboxyglutamate (gla) protein	11.0	Publications
24	PTH2R	parathyroid hormone 2 receptor	11.0	Publications
25	SPSB1	splA/ryanodine receptor domain and SOCS box containing 1	11.0	Publications
26	ALPP	alkaline phosphatase, placental	11.0	Publications
27	KL	klotho	11.0	Publications
28	ADM	adrenomedullin	11.0	Publications
29	VDR	vitamin D (1,25- dihydroxyvitamin D3) receptor	11.0	Publications
30	CRTAC1	cartilage acidic protein 1	11.0	Publications
31	CAPN2	calpain 2, (m/II) large subunit	11.0	Publications
32	PTHLH	parathyroid hormone-like hormone	11.0	Publications
33	SLPI	secretory leukocyte peptidase inhibitor	11.0	Publications
34	IAPP	islet amyloid polypeptide	11.0	Publications
35	IL6R	interleukin 6 receptor	11.0	Publications
36	LBR	lamin B receptor	11.0	Publications
37	RET	ret proto-oncogene	11.0	Publications
38	PAX5	paired box 5	11.0	Publications
39	GC	group-specific component (vitamin D binding protein)	11.0	Publications
40	GAST	gastrin	11.0	Publications
41	CXADR	coxsackie virus and adenovirus receptor	11.0	Publications
42	COL1A1	collagen, type I, alpha 1	11.0	Publications
43	TH	tyrosine hydroxylase	11.0	Publications
44	F10	coagulation factor X	11.0	Publications
45	CD36	CD36 molecule (thrombospondin receptor)	11.0	Publications
46	TNFSF11	tumor necrosis factor (ligand) superfamily, member 11	11.0	Publications
47	TNFRSF11B	tumor necrosis factor receptor superfamily, member 11b	11.0	Publications
48	B2M	beta-2-microglobulin	11.0	Publications
49	SHBG	sex hormone-binding globulin	11.0	Publications
50	LRP2	low density lipoprotein receptor-related protein 2	11.0	Publications

Pathways related to primary hyperparathyroidism according to GeneDecks:

(show all 50)

id	Pathway	Score	Top Affiliating Genes
1	Breast Cancer Regulation by Stathmin136	10.8	FGF23
2	Class B/2 (Secretin family receptors)38	10.5	ADM, PTHLH, PTH2R, PTH1R, PTH, CALCA
3	Development_Hedgehog and PTH signaling pathways in bone and cartilage development41	10.1	BGLAP, CCND1, GNAS, TNFSF11, PTH, PTH1R
4	Development Hedgehog and PTH signaling pathways in bone and cartilage development10	10.1	PRKAR1A, VDR, BGLAP, CCND1, GNAS, TNFSF11
5	Pathways in cancer20	9.9	CCND1, FGF23, CDKN1B, BRCA2, RET
6	Gastric acid secretion20	9.9	GAST, SST, GNAS, CFTR, KCNQ1
7	JNK Pathway36	9.6	KITLG, IL6, IL6R, CXCL12
8	Cytokine production by Th17 cells in CF41	9.4	CSF3, IL6R, IL6, CFTR
9	ILK Signaling36	9.4	CXCL12, COL1A1, GH1, IGF1, FGF23, KITLG
10	ERK Signaling36	9.3	CSF3, CXCL12, PRKAR1A, COL1A1, TNFSF11, CAPN2
11	Malaria20	9.3	CSF3, TNF, IL6, CD36, SELE
12	Adipocytokines & Insulin Signaling37	9.3	LEP, ADIPOQ, INS
13	Endothelin-1 Signaling Pathway36	9.3	IL6, CCL27, TNFSF11, CXCL12, CSF3
14	Akt Signaling36	9.2	CXCL12, TNFSF11, TNF, CCND1, CCL27, IL6R
15	Selected targets of HNF110	9.2	ALB, IAPP, IGFBP1, INS, CFTR
16	TGF-Beta Pathway36	9.2	CXCL12, GH1, IGF1, CCL27, IL6R, IL6
17	Nuclear Receptor Activation by Vitamin-A36	9.1	CXCL12, PRKAR1A, GH1, IGF1, IL6, FGF23
18	MIF Mediated Glucocorticoid Regulation36	9.1	CXCL12, TNFSF11, TNF, CCL27, IL6, CSF3
19	MIF Regulation of Innate Immune Cells36	9.1	CSF3, CXCL12, TNFSF11, TNF, CCL27, IL6
20	Hematopoietic cell lineage20	9.1	EPO, CSF3, TNF, IL6R, IL6, CD36
21	Molecular Mechanisms of Cancer36	9.1	CXCL12, COL1A1, TNFSF11, GH1, CCND1, CCL27
22	IL-6 Pathway36	9.0	IL6, IL6R, CCL27, TNF, TNFSF11, CXCL12
23	Jak-STAT signaling pathway20	9.0	EPO, PRL, GH1, CCND1, IL6R, LEP
24	eNOS Signaling36	9.0	CXCL12, PRKAR1A, NOS3, GH1, IGF1, IL6
25	all-trans-Retinoic Acid Signaling in Brain36	9.0	CSF3, CXCL12, TNFSF11, TNF, CCL27, IL6
26	Adipocytokine signaling pathway20	9.0	ADIPOQ, POMC, TNF, CD36, LEP
27	PEDF Induced Signaling36	8.9	CSF3, CXCL12, TNFSF11, TNF, CCL27, IL6
28	Transcription Role of VDR in regulation of genes involved in osteoporosis10	8.9	VDR, COL1A1, BGLAP, IL6, IGF1, CALCA
29	Transcription_Role of VDR in regulation of genes involved in osteoporosis41	8.9	IL6, IGF1, CALCA, TNF, TNFRSF11B, TNFSF11
30	STAT3 Pathway36	8.9	CSF3, CXCL12, TNFSF11, TNF, CCL27, IL6R
31	Estrogen Pathway36	8.8	CXCL12, PRKAR1A, NOS3, GH1, IGF1, CCND1
32	PPAR Pathway36	8.8	CXCL12, TNF, GH1, IGF1, IL6, FGF23
33	Apoptotic Pathways in Synovial Fibroblasts36	8.8	CXCL12, TNF, GH1, IGF1, IL6, FGF23
34	NF-KappaB (p50-p65) Pathway36	8.8	CXCL12, PRKAR1A, TNF, GH1, IGF1, IL6
35	Selected targets of GCR-alpha10	8.7	NR1I3, TNFSF11, IGFBP1, IL6, INS, LEP
36	Pancreatic Adenocarcinoma36	8.7	CXCL12, GH1, IGF1, CCND1, IL6, FGF23
37	NF-KappaB Family Pathway36	8.7	FGF23, IL6, IGF1, GH1, TNF, CXCL12
38	mTOR Pathway36	8.7	CXCL12, KITLG, INS, FGF23, IL6, IGF1
39	JAK-STAT Pathway36	8.7	EPO, CXCL12, PRL, GH1, IGF1, CCL27
40	Cellular Apoptosis Pathway36	8.7	CXCL12, TNF, GH1, IGF1, IL6, FGF23
41	MAPK Family Pathway36	8.7	CXCL12, TNF, GH1, IGF1, CCL27, IL6R
42	eIF2 Pathway36	8.7	CXCL12, GH1, IGF1, IL6, FGF23, INS
43	Tec Kinases Signaling36	8.6	IL6, IL6R, CCL27, IGF1, GH1, TNF
44	p53 Mediated Apoptosis36	8.6	CXCL12, GH1, IGF1, IL6, FGF23, KITLG
45	PAK Pathway36	8.3	CSF3, CXCL12, TNFSF11, TNF, GH1, IGF1
46	p70S6K Signaling36	8.3	CXCL12, GH1, IGF1, IL6, FGF23, INS
47	p38 Signaling36	8.2	CSF3, CXCL12, TNFSF11, TNF, GH1, IGF1
48	Antioxidant Action of Vitamin-C36	8.2	CSF3, CXCL12, PRKAR1A, TNFSF11, TNF, GH1
49	Rho Family GTPases36	8.2	CSF3, CXCL12, COL1A1, TNFSF11, TNF, GH1
50	Cytokine-cytokine receptor interaction20	7.3	TNFSF11, PRL, CXCL12, CSF3, EPO, TNFRSF11B

Compounds related to primary hyperparathyroidism according to GeneDecks:

(show top 50)    (show all 390)

id	Compound	Score	Top Affiliating Genes
1	glucose32	10.6	MIP, CASR, PTH, PTHLH, PRKAR1A, GAST
2	pamidronate32 9 9	11.3	BGLAP, B2M, CD36, IL6, ALPP, CASR
3	isoproterenol32 9 9	11.3	KCNQ1, CHGA, LBR, CFTR, IAPP, GNAS
4	pge232	9.3	SELE, CFTR, CCL27, GNAS, CASR, TNFRSF11B
5	ascorbic acid32 18	10.0	VDR, BGLAP, CFTR, CD36, ALPP, F10
6	aspartate32	8.9	RET, GC, VDR, B2M, CFTR, CCL27
7	25-hydroxyvitamin d32	8.9	GC, VDR, BGLAP, PAX5, LEP, FGF23
8	pyridinoline32	8.9	BGLAP, PAX5, CD36, IGF1, ALPP, CALCA
9	alendronate32 9 9	10.8	VDR, BGLAP, PAX5, CD36, IGF1, ALPP
10	progesterone32 42 9 18 9	12.8	BRCA2, CHGA, CDKN1B, CCND1, GNAS, GH1
11	1,25 dihydroxy vitamin d332	8.8	GC, VDR, BGLAP, CDKN1B, FGF23, IGF1
12	deoxypyridinoline32	8.8	VDR, BGLAP, PAX5, CD36, IL6R, CCL27
13	histamine32 18	9.6	KITLG, VWF, SELE, BGLAP, CHGA, LBR
14	cysteine32	8.5	VDR, BGLAP, KCNQ1, LBR, CFTR, MIP
15	estradiol32 9 18 9	11.5	KITLG, GC, SERPINE1, BRCA2, CDKN1B, IL6R
16	raloxifene32 9 9	10.4	VWF, SERPINE1, VDR, BGLAP, PAX5, CD36
17	dihydrotestosterone32 9 18 9	11.2	SERPINE1, VDR, BGLAP, LEP, IGFBP1, IGF1
18	simvastatin32 34 42 9 18 9	13.1	KITLG, VWF, SELE, SERPINE1, BGLAP, PAX5
19	ly29400232	8.1	RET, SELE, LEP, CDKN1B, IL6, CCND1
20	nifedipine32 9 9	10.0	SELE, SERPINE1, BGLAP, LEP, CHGA, LBR
21	h2o232	7.9	KITLG, VWF, BRCA2, BGLAP, LEP, LBR
22	ribonucleic acid32	7.8	RET, KITLG, CHGA, IL6R, IGFBP1, IGF1
23	cyclosporin a32 42	8.7	KITLG, VWF, VDR, BGLAP, LEP, LBR
24	heparin32 9 18 9	10.6	LRP2, KITLG, VWF, SERPINE1, BGLAP, LBR
25	metformin32 34 9 9	10.6	VWF, SERPINE1, LEP, INS, IGFBP1, IGF1
26	glutamate32	7.6	GC, VDR, LEP, CFTR, CDKN1B, MIP
27	gnrh32	7.5	KITLG, SERPINE1, LEP, CFTR, INS, IGFBP1
28	dehydroepiandrosterone sulfate32	7.4	PAX5, LEP, INS, IGFBP1, IGF1, GH1
29	acetylcholine32 9 18 9	10.4	VWF, LEP, CHGA, LBR, CFTR, IAPP
30	octreotide32 42 9 9	10.3	CHGA, INS, FGF23, IGFBP1, IGF1, GNAS
31	calcium32 9 18 9	10.2	KL, KITLG, VWF, GCM2, BGLAP, PAX5
32	epinephrine32 9 18 9	9.9	KITLG, SELE, KCNQ1, LEP, CHGA, LBR
33	cisplatin32 34 9 9	9.9	KITLG, BRCA2, BGLAP, LEP, CHGA, LBR
34	paraffin32	6.8	RET, KITLG, VWF, BRCA2, BGLAP, PAX5
35	adenylate32	6.8	KITLG, VWF, GC, SELE, SERPINE1, VDR
36	creatinine32	6.7	KITLG, VWF, GC, SELE, VDR, LEP
37	testosterone32 9 18 9	9.6	RET, KITLG, GC, SELE, BRCA2, VDR
38	tamoxifen32 34 9 9	9.5	SELE, BRCA2, VDR, BGLAP, LEP, CHGA
39	indomethacin32 9 9	8.1	LEP, B2M, CFTR, IL6, IGFBP1, IAPP
40	norepinephrine32 9 18 9	8.7	KITLG, VWF, SELE, LEP, CHGA, LBR
41	thyroxine32 18	6.6	LRP2, VWF, GC, VDR, BGLAP, LEP
42	vitamin d32	5.6	LRP2, GC, SERPINE1, VDR, BGLAP, PAX5
43	methotrexate32 34 42 9 9	9.6	KITLG, SELE, SERPINE1, BRCA2, LEP, CDKN1B
44	hydrocortisone32 9 9	7.5	KITLG, BGLAP, CD36, INS, IL6, IGFBP1
45	alanine32	5.5	RET, KITLG, VWF, SELE, VDR, BGLAP
46	cholesterol32 9 18 9	7.9	LRP2, KITLG, VWF, GC, SELE, SERPINE1
47	lipid32	4.8	LRP2, RET, KITLG, GC, SELE, SERPINE1
48	retinoic acid32 42 18	6.6	LRP2, RET, KITLG, VWF, GC, SERPINE1
49	vegf32	3.8	KL, RET, KITLG, VWF, SELE, SERPINE1
50	dexamethasone32 42 34 9 9	6.9	KITLG, VWF, SERPINE1, VDR, BGLAP, LEP

Cellular components related to primary hyperparathyroidism according to GeneDecks:

id	Name	GO ID	Score	Top Affiliating Genes
1	secretory granule	GO:030141	9.4	BRCA2, CHGA, INS, GHRL, POMC
2	extracellular space	GO:005615	3.2	EPO, IGF1, IGFBP1, CCL27, IL6R, IL6
3	extracellular region	GO:005576	2.9	GAST, EPO, ADIPOQ, KL, ALB, IAPP

Biological processes related to primary hyperparathyroidism according to GeneDecks:

(show all 48)

id	Name	GO ID	Score	Top Affiliating Genes
1	positive regulation of vitamin D 24-hydroxylase activity	GO:010980	10.7	VDR, FGF23, CYP27B1
2	osteoblast development	GO:002076	10.7	PTHLH, PTH1R, MEN1, BGLAP
3	positive regulation of cAMP biosynthetic process	GO:030819	10.6	ADM, PTHLH, PTH, CALCA
4	negative regulation of bone resorption	GO:045779	10.6	IAPP, CALCA, TNFRSF11B
5	vitamin D metabolic process	GO:042359	10.5	LRP2, GC, CYP27B1
6	cellular calcium ion homeostasis	GO:006874	10.4	GCM2, VDR, CASR, PTH, CXCL12
7	monocyte chemotaxis	GO:002548	10.2	TNFSF11, CALCA, IL6R, IL6
8	organ regeneration	GO:031100	10.1	ADM, CXCL12, CCND1, BAAT, LRP2
9	aging	GO:007568	10.0	EPO, ADM, NOS3, PTH1R, CALCA, VDR
10	positive regulation of vasodilation	GO:045909	10.0	INS, CALCA, NOS3, ADM
11	adenylate cyclase-activating G-protein coupled receptor signaling pathway	GO:007189	10.0	CALCA, PTH, PTH1R, PTHLH
12	skeletal system development	GO:001501	10.0	COL1A1, PTHLH, PTH1R, PTH, TNFRSF11B, IGF1
13	response to estrogen stimulus	GO:043627	10.0	EPO, CYP27B1, TNFRSF11B, GHRL, CCND1, BGLAP
14	lactation	GO:007595	9.9	PRL, CCND1, VDR, GC
15	response to ethanol	GO:045471	9.9	ADIPOQ, TH, NOS3, CCND1, BGLAP
16	response to estradiol stimulus	GO:032355	9.8	NOS3, GH1, VDR, BRCA2, GC
17	response to mechanical stimulus	GO:009612	9.7	SOST, CXCL12, NOS3, TNF, BGLAP
18	positive regulation of glucose import	GO:046326	9.7	ADIPOQ, PTH, IGF1, INS
19	positive regulation of interleukin-6 production	GO:032755	9.7	TNF, IL6R, IL6, CD36
20	cell-cell signaling	GO:007267	9.6	ADM, POMC, SST, PTHLH, PTH, CALCA
21	defense response to Gram-positive bacterium	GO:050830	9.6	CD36, IL6, IL6R, TNF
22	positive regulation of MAP kinase activity	GO:043406	9.6	TNFSF11, TNF, GH1, KITLG
23	positive regulation of JAK-STAT cascade	GO:046427	9.5	IL6, GH1, PRL
24	response to glucocorticoid stimulus	GO:051384	9.5	ADIPOQ, ADM, TNF, IL6, BGLAP, SERPINE1
25	G-protein coupled receptor signaling pathway	GO:007186	9.5	GAST, CXCL12, SST, PTH2R, PTH1R, PTH
26	organ morphogenesis	GO:009887	9.5	TH, TNFSF11, TNF, PAX5, VDR
27	endocrine pancreas development	GO:031018	9.5	IAPP, IL6R, IL6, INS
28	regulation of blood pressure	GO:008217	9.4	POMC, NOS3, CALCA, CHGA, LEP
29	female pregnancy	GO:007565	9.4	ADM, PRL, PTHLH, GNAS, LEP, GC
30	MAPK cascade	GO:000165	9.4	NF1, TNF, MEN1, INS, RET
31	positive regulation of DNA replication	GO:045740	9.4	EPO, IGF1, INS, KITLG
32	leukocyte tethering or rolling	GO:050901	9.3	SELE, LEP, TNF
33	positive regulation of tyrosine phosphorylation of Stat3 protein	GO:042517	9.3	GH1, IL6R, IL6, LEP
34	positive regulation of protein kinase B signaling cascade	GO:051897	9.1	INS, IGF1, F10, TNF, TNFSF11
35	platelet degranulation	GO:002576	9.1	ALB, IGF1, CD36, SERPINE1, VWF
36	positive regulation of smooth muscle cell proliferation	GO:048661	9.0	IL6, IL6R, IGF1, TNF
37	response to drug	GO:042493	8.9	ABCB1, NOS3, SST, TNFRSF11B, TNF, CCND1
38	positive regulation of peptidyl-tyrosine phosphorylation	GO:050731	8.8	KITLG, ADIPOQ, GH1, IGF1, IL6R, IL6
39	regulation of insulin secretion	GO:050796	8.7	PRKAR1A, TNF, GNAS, INS, LEP
40	platelet activation	GO:030168	8.7	COL1A1, ALB, IGF1, IL6, CD36, SERPINE1
41	positive regulation of transcription from RNA polymerase II promoter	GO:045944	8.7	TNF, TNFSF11, PTH, POMC, IGF1, IL6
42	signal transduction	GO:007165	8.6	TG, PRKAR1A, CXCL12, POMC, ADM, EPO
43	blood coagulation	GO:007596	8.6	CXADR, PRKAR1A, COL1A1, NOS3, F10, GNAS
44	negative regulation of cell proliferation	GO:008285	8.5	ADM, NOS3, SST, CYP27B1, PTHLH, PTH1R
45	positive regulation of MAPK cascade	GO:043410	8.5	IGF1, IL6R, IL6, INS, CD36, LEP
46	response to hypoxia	GO:001666	8.4	ADIPOQ, ADM, CXCL12, TH, NF1, NOS3
47	positive regulation of cell proliferation	GO:008284	7.7	EPO, ADM, CSF3, PTHLH, PTH1R, IGF1
48	negative regulation of apoptotic process	GO:043066	7.0	EPO, CXCL12, TNF, GHRL, ALB, IL6

Molecular functions related to primary hyperparathyroidism according to GeneDecks:

(show all 8)

id	Name	GO ID	Score	Top Affiliating Genes
1	vitamin D binding	GO:005499	10.0	KL, GC, VDR
2	peptide hormone receptor binding	GO:051428	9.6	LEP, PTH, PTHLH
3	receptor binding	GO:005102	9.4	ADIPOQ, ADM, POMC, CXCL12, CXADR, CALCA
4	protease binding	GO:002020	9.1	TNF, INS, BRCA2, SERPINE1
5	cytokine activity	GO:005125	8.6	ADIPOQ, CSF3, TNFSF11, TNFRSF11B, TNF, IL6
6	growth factor activity	GO:008083	7.9	CSF3, CXCL12, GH1, IGF1, IL6, FGF23
7	hormone activity	GO:005179	6.9	KL, GAST, EPO, ADIPOQ, ADM, POMC
8	protein binding	GO:005515	4.0	COL1A1, NOS3, SPINK1, TNF, AIP, GH1